Medical treatment of pancreatic cancer: New hopes after 10years of gemcitabine

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 5, 2011, Pages 364-374

  Trouilloud, Isabelle ^a   Dubreuil, Olivier ^a   Boussaha, Tarek ^a   Lepère, Céline ^a   Landi, Bruno ^a   Zaanan, Aziz ^a   Bachet, Jean Baptiste ^a   Taieb, Julien ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CONATUMUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; EVEROLIMUS; EXATECAN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; GEMOX; INTETUMUMAB; IRINOTECAN; MASITINIB; MITOMYCIN; OXALIPLATIN; PLACEBO; PLATINUM DERIVATIVE; RALTITREXED; RUBITECAN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLESTASIS; DISEASE FREE SURVIVAL; HUMAN; ONCOGENE C KIT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79956349638     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.02.002     Document Type: Review

References (81)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46(4):765-781.
2. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Ritchey J., Stewart A.K., Winchester D.P., et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007, 110(4):738-744.
3. Palmer D.H., Stocken D.D., Hewitt H., Markham C.E., Hassan A.B., Johnson P.J., et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg. Oncol 2007, 14(7):2088-2096.
4. Heinrich S., Pestalozzi B.C., Schäfer M., Weber A., Bauerfeind P., Knuth A., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(15):2526-2531.
5. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120(8):899-903.
6. Kosuge T., Kiuchi T., Mukai K., Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006, 36(3):159-165.
7. Bakkevold K.E., Arnesjø B., Dahl O., Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993, 29A(5):698-703.
8. Takada T., Amano H., Yasuda H., Nimura Y., Matsushiro T., Kato H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95(8):1685-1695.
9. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1200-1210.
10. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277.
11. Regine W.F., Winter K.A., Abrams R.A., Safran H., Hoffman J.P., Konski A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299(9):1019-1026.
12. Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304(10):1073-1081.
13. Mallinson C.N., Rake M.O., Cocking J.B., Fox C.A., Cwynarski M.T., Diffey B.L., et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980, 281(6255):1589-1591.
14. Glimelius B., Hoffman K., Sjödén P.O., Jacobsson G., Sellström H., Enander L.K., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7(6):593-600.
15. Palmer K.R., Kerr M., Knowles G., Cull A., Carter D.C., Leonard R.C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994, 81(6):882-885.
16. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
17. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21(18):3402-3408.
18. Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27(23):3778-3785.
19. Ciccolini J., Dahan L., André N., Evrard A., Duluc M., Blesius A., et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010, 28(1):160-165.
20. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006, 66(7):3928-3935.
21. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1):187-195.
22. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20(15):3270-3275.
23. Di Costanzo F., Carlini P., Doni L., Massidda B., Mattioli R., Iop A., et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005, 93(2):185-189.
24. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schüller J., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25(16):2212-2217.
25. Bernhard J., Dietrich D., Scheithauer W., Gerber D., Bodoky G., Ruhstaller T., et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 2008, 26(22):3695-3701.
26. Scheithauer W., Schüll B., Ulrich-Pur H., Schmid K., Raderer M., Haider K., et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003, 14(1):97-104.
27. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27(33):5513-5518.
28. Heinemann V., Boeck S., Hinke A., Labianca R., Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8:82.
29. Colucci G., Giuliani F., Gebbia V., Biglietto M., Rabitti P., Uomo G., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002, 94(4):902-910.
30. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Cartenì G., Massidda B., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28(10):1645-1651.
31. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schönekäs H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24(24):3946-3952.
32. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., André T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516.
33. Rocha Lima C.M., Green M.R., Rotche R., Miller W.H., Jeffrey G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22(18):3776-3783.
34. Stathopoulos G.P., Syrigos K., Aravantinos G., Polyzos A., Papakotoulas P., Fountzilas G., et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006, 95(5):587-592.
35. Abou-Alfa G.K., Letourneau R., Harker G., Modiano M., Hurwitz H., Tchekmedyian N.S., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24(27):4441-4447.
36. Oettle H., Richards D., Ramanathan R.K., van Laethem J.L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005, 16(10):1639-1645.
37. Reni M., Cordio S., Milandri C., Passoni P., Bonetto E., Oliani C., et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005, 6(6):369-376.
38. Stathopoulos G.P., Mavroudis D., Tsavaris N., Kouroussis C., Aravantinos G., Agelaki S., et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001, 12(1):101-103.
39. Shepard R.C., Levy D.E., Berlin J.D., Stuart K., Harris J.E., Aviles V., et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology 2004, 66(4):303-309.
40. Ryan D.P., Kulke M.H., Fuchs C.S., Grossbard M.L., Grossman S.R., Morgan J.A., et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002, 94(1):97-103.
41. Rougier P., Adenis A., Ducreux M., de Forni M., Bonneterre J., Dembak M., et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000, 36(8):1016-1025.
42. Lutz M.P., Van Cutsem E., Wagener T., Van Laethem J., Vanhoefer U., Wils J.A., et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 2005, 23(36):9250-9256.
43. Cullinan S., Moertel C.G., Wieand H.S., Schutt A.J., Krook J.E., Foley J.F., et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990, 65(10):2207-2212.
44. Ducreux M., Rougier P., Pignon J., Douillard J., Seitz J., Bugat R., et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002, 13(8):1185-1191.
45. Ducreux M., Mitry E., Ould-Kaci M., Boige V., Seitz J.F., Bugat R., et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004, 15(3):467-473.
46. Boeck S., Hoehler T., Seipelt G., Mahlberg R., Wein A., Hochhaus A., et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008, 19(2):340-347.
47. Mabro M., Artru P., André T., Flesch M., Maindrault-Goebel F., Landi B., et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006, 94(9):1287-1292.
48. Taïeb J., Lecomte T., Aparicio T., Asnacios A., Mansourbakht T., Artru P., et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 2007, 18(3):498-503.
49. Conroy T., Paillot B., François E., Bugat R., Jacob J., Stein U., et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe tumeurs digestives of the Fédération nationale des Centres de lutte contre le cancer study. J Clin Oncol 2005, 23(6):1228-1236.
50. Conroy T., Desseigne F., Ychou M., Ducreux M., Bouche O., Guimbaud R., et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol (Meeting Abstracts) 2010, 28(Suppl. 15):4010.
51. Xiong H.Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R.A., Deutsch J., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004, 22(13):2610-2616.
52. Philip P.A., Benedetti J., Corless C.L., Wong R., O'Reilly E.M., Flynn P.J., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010, 28(22):3605-3610.
53. Cascinu S., Berardi R., Labianca R., Siena S., Falcone A., Aitini E., et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008, 9(1):39-44.
54. Kullmann F., Hollerbach S., Dollinger M.M., Harder J., Fuchs M., Messmann H., et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 2009, 100(7):1032-1036.
55. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
56. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: national Cancer Institute of Canada Clinical Trials Group Study PA.3 [Internet]. Cancer 2010; [cité 2010 Déc 6] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20824720.
57. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362(17):1605-1617.
58. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23(31):8033-8040.
59. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28(22):3617-3622.
60. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27(13):2231-2237.
61. Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W.L., Szawlowski A., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004, 22(8):1430-1438.
62. Spano J., Chodkiewicz C., Maurel J., Wong R., Wasan H., Barone C., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371(9630):2101-2108.
63. Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, et al. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study [Internet]. Invest New Drugs 2009; [cité 2010 Nov 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/19714296.
64. Richards D.A., Boehm K.A., Waterhouse D.M., Wagener D.J., Krishnamurthi S.S., Rosemurgy A., et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006, 17(7):1096-1102.
65. Friess H., Langrehr J.M., Oettle H., Raedle J., Niedergethmann M., Dittrich C., et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006, 6:285.
66. Alberts S.R., Foster N.R., Morton R.F., Kugler J., Schaefer P., Wiesenfeld M., et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005, 16(10):1654-1661.
67. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A.C. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87(2):161-167.
68. Moore M.J., Hamm J., Dancey J., Eisenberg P.D., Dagenais M., Fields A., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21(17):3296-3302.
69. Kindler H.L., Richards D.A., Stephenson J., Garbo L.E., Rocha Lima C.S., Safran H., et al. A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol (Meeting Abstracts) 2010, 28(Suppl. 15):4035.
70. Mitry E., Hammel P., Deplanque G., Mornex F., Levy P., Seitz J., et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2010, 66(2):395-403.
71. Hammel P., Mornex F., Deplanque G., Mitry E., Levy P., Seitz J., et al. Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study. J Clin Oncol (Meeting Abstracts) 2009, 27(15S):4617.
72. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009, 27(2):193-198.
73. Bachet J., Mitry E., Lièvre A., Lepère C., Vaillant J., Declety G., et al. Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. Gastroenterol Clin Biol 2009, 33(10-11):1036-1044.
74. Jacobs A.D., Burris H.A., Rivkin S., Ritch P.S., Eisenberg P.D., Mettinger K.L. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol (Meeting Abstracts) 2004, 22(Suppl. 14):4013.
75. Ciuleanu T.E., Pavlovsky A.V., Bodoky G., Garin A.M., Langmuir V.K., Kroll S., et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009, 45(9):1589-1596.
76. Ulrich-Pur H., Raderer M., Verena Kornek G., Schüll B., Schmid K., Haider K., et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003, 88(8):1180-1184.
77. Oettle H., Pelzer U., Stieler J., Hilbig A., Roll L., Schwaner I., et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol (Meeting Abstracts) 2005, 23(Suppl. 16):4031.
78. Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Gorner M., et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol (Meeting Abstracts) 2008, 26(Suppl. 15):4508.
79. Taïeb J., Lecomte T., Ezenfis J., Artru P., Mitry E., Boige V., et al. 5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer. Gastroenterol Clin Biol 2002, 26(6-7):605-609.
80. Dahan L., Bonnetain F., Ychou M., Mitry E., Gasmi M., Raoul J., et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010, 59(11):1527-1534.
81. Yoo C., Hwang J.Y., Kim J., Kim T.W., Lee J.S., Park D.H., et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009, 101(10):1658-1663.